Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults A double-blind randomized trial

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 6, 2013, Pages 1254-1262

  Leroux Roels, Geert ^a   Clément, Frédéric ^a   Vandepapelière, Pierre ^b   Fourneau, Marc ^c   Heineman, Thomas ^d   Dubin, Gary ^d  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GlaxoSmithKline Vaccines ^*

^c GSK   (Belgium)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Adjuvant; Glycoprotein D herpes virus; Herpes simplex virus; HSV vaccine; Immunogenicity; Protein subunit vaccine; Safety

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM SALT; GAMMA INTERFERON; GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; PHOSPHORYL LIPID A; PRESERVATIVE; VIRUS DNA;

ADULT; ARTICLE; BLOOD SAMPLING; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GENITAL HERPES; HEMATOMA; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOGENICITY; INCIDENCE; INJECTION SITE COLORATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJURY; MALE; MUSCLE RIGIDITY; NORMAL HUMAN; PHARYNGITIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS STRAIN;

ADJUVANT; GLYCOPROTEIN D HERPES VIRUS; HERPES SIMPLEX VIRUS; HSV VACCINE; IMMUNOGENICITY; PROTEIN SUBUNIT VACCINE; SAFETY;

ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HERPES GENITALIS; HERPESVIRUS VACCINES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INCIDENCE; LIPID A; MALE; VACCINATION; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS; YOUNG ADULT;

EID: 84880652594     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24043     Document Type: Article

References (27)

1. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. [A.]. Bull World Health Organ 2008; 86:805-12; PMID:18949218; http://dx.doi.org/10.2471/BLT.07.046128.
2. Bernstein DI. Effects of prior HSV-1 infection on genital HSV-2 infection. Prog Med Virol 1991; 38:109-27; PMID:1647042.
3. Nahmias AJ, Lee FK, Beckman-Nahmias S. Seroepidemiological and-sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990; 69:19-36; PMID:2175939.
4. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002; 186(Suppl 1):S3-28; PMID:12353183; http://dx.doi.org/10.1086/343739.
5. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964-73; PMID:16926356; http://dx.doi.org/10.1001/jama. 296.8.964.
6. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197-202; PMID:1309413.
7. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al.; Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20; PMID:14702423; http://dx.doi.org/10.1056/NEJMoa035144.
8. Marchant J, Roe A. Genital herpes: recognizing and addressing patient's needs. Herpes 1997; 4:36-41.
9. Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, Shafran SD, et al.; GlaxoSmithKline Herpes Vaccine Study Group. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 2005; 40:1271-81; PMID:15825029; http://dx.doi.org/10.1086/429240.
10. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al.; GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347:1652-61; PMID:12444179; http://dx.doi.org/10.1056/NEJMoa011915.
11. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al.; Herpevac Trial for Women. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366:34-43; PMID:22216840; http://dx.doi.org/10.1056/ NEJMoa1103151.
12. Mikloska Z, Cunningham AL. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J Gen Virol 1998; 79:353-61; PMID:9472620.
13. Schmid DS, Thieme ML, Gary HE Jr., Reeves WC. Characterization of T cell responses to herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) using a TNF-beta ELISpot cytokine assay. Arch Virol 1997; 142:1659-71; PMID:9672626; http://dx.doi.org/10.1007/s007050050187.
14. Rosenthal KL, Smiley JR, South S, Johnson DC. Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes. J Virol 1987; 61:2438-47; PMID:3037106.
15. Eisenberg RJ, Ponce de Leon M, Cohen GH. Comparative structural analysis of glycoprotein gD of herpes simplex virus types 1 and 2. J Virol 1980; 35:428-35; PMID:6255183.
16. Dix RD, Pereira L, Baringer JR. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infect Immun 1981; 34:192-9; PMID:6271681.
17. Eing BR, Kühn JE, Braun RW. Neutralizing activity of antibodies against the major herpes simplex virus type 1 glycoproteins. J Med Virol 1989; 27:59-65; PMID:2466100; http://dx.doi.org/10.1002/jmv.1890270113.
18. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723-39; PMID:17931153; http://dx.doi.org/10.1586/14760584.6.5. 723.
19. Leroux-Roels G, Moreaux E, Desombre I, Crayne O, Francotte M, Pala P. Persistence of humoral and cellular immune response and booster effect following vaccination with herpes simplex (gD2t) candidate vaccine with MPL [abstract]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy 1994; 205.
20. Ahmad A, Sharif-Askari E, Fawaz L, Menezes J. Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction. J Virol 2000; 74:7196-203; PMID:10906173; http://dx.doi.org/10.1128/ JVI.74.16.7196-7203.2000.
21. Khodai T, Chappell D, Christy C, Cockle P, Eyles J, Hammond D, et al. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immunol 2011; 18:1702-9; PMID:21852545; http://dx.doi.org/10.1128/ CVI.05071-11.
22. Hosken N, McGowan P, Meier A, Koelle DM, Sleath P, Wagener F, et al. Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol 2006; 80:5509-15; PMID:16699031; http://dx.doi.org/10.1128/JVI.02659-05.
23. Morello CS, Levinson MS, Kraynyak KA, Spector DH. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol 2011; 85:3461-72; PMID:21270160; http://dx.doi.org/10.1128/JVI.02521-10.
24. Cattamanchi A, Posavad CM, Wald A, Baine Y, Moses J, Higgins TJ, et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol 2008; 15:1638-43; PMID:18784341; http://dx.doi.org/10.1128/CVI. 00167-08.
25. Dervillez X, Gottimukkala C, Kabbara KW, Nguyen C, Badakhshan T, Kim SM, et al. Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine. Future Virol 2012; 7:371-8; PMID:22701511; http://dx.doi.org/10.2217/fvl.12.22.
26. Karpinski KF, Hayward S, Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods 1987; 103:189-94; PMID:3668258; http://dx.doi.org/10.1016/0022-1759(87)90289-4.
27. Leroux-Roels G, Van Hecke E, Michielsen W, Voet P, Hauser P, Pêtre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. Vaccine 1994; 12:812-8; PMID:7975860; http://dx.doi.org/10.1016/0264-410X(94) 90290-9.